Key statistics dashboard for Ocugen, Inc. (OCGN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigme...
Stock Data
| Price | $1.00 |
| Market Cap | $339M |
| Beta | 2.81 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -3.93 |
| Price / Book | -20.32 |
| P/S | 73.56 |
| P/FCF | -5.49 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -1590.59% |
| EBITDA Margin | -1531.13% |
| Operating Margin | -1504.43% |
| Net Margin | -1786.27% |
Financial Health
| Current Ratio | 0.80 |
| Quick Ratio | 0.80 |
| Cash Ratio | 0.75 |
| Debt / Equity | -5.31 |
| Debt / Assets | 70.84% |
| Interest Coverage | -8.16 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -13.40 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | -0.05 |
| Cash per share | 0.30 |
| FCF per share | -0.18 |
| Tangible Book Value per share | -0.05 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 0.83 |
Related companies: ADCT · ALMS · CMPX · FULC · LCTX · LXRX · NGNE
Explore sector: Healthcare · Biotechnology
More sections of OCGN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks